Dihydropyridine neuropeptide Y Y1 receptor antagonists 2: Bioisosteric urea replacements

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 2, 2004, Pages 507-521

  Poindexter, Graham S ^a   Bruce, Marc A ^a   Breitenbucher, J Guy ^a   Higgins, Mendi A ^a   Sit, S Y ^a   Romine, Jeffrey L ^a   Martin, Scott W ^a   Ward, Sally A ^a   McGovern, Rachel T ^a   Clarke, Wendy ^a   Russell, John ^a   Antal Zimanyi, Ildiko ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 193885; DICARBOXYLIC ACID DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; UREA DERIVATIVE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG BIOAVAILABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHYLATION; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0347951125     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2003.10.016     Document Type: Article

References (56)

1. Tatemoto K., Carlquist M., Mutt V. Nature. 269:1982;659.
2. Wahlestedt C., Reis D. J. Ann. Rev. Pharmacol. Toxicol. 33:1993;309.
3. Gehlert D.R. Neuropeptides. 33:1999;329.
4. Antal-Zimanyi I., Fathi Z., Poindexter G.S. Curr. Pharm. Des. 4:1998;349.
5. Turton M.D., O'Shea D., Bloom S.R. Neuropeptide Y and Drug Develop. 40:1997;15.
6. Gehlert D.R. Proc. Soc. Exp. Biol. Med. 218:1998;7.
7. Blomqvist A.G., Herzog H. Trends Neurosci. 20:1997;294.
8. Inui A. Trends Pharm. Sci. 20:1999;43.
9. 2 receptor might also be involved in the regulation of energy homeostasis and satiety: Herzog H. Drug News Perspt. 15:2002;506.
10. Parker E., Van Heek M., Stamford A. Eur. J. Pharmacol. 440:2002;173.
11. Kanatani A., Ishihara A., Fukami T., Ihara M. Drugs Future. 27:2002;589.
12. Antal-Zimanyi I., Poindexter G.S. Drug Dev. Res. 48:2000;94.
13. Stamford A.W., Parker E.M. Ann. Rep. Med. Chem. 34:1999;31.
14. Gehlert D.R., Hipskind P.A. Exp. Opin. Invest. Drugs. 6:1997;1827.
15. Rudolf K., Eberlein W., Engel W., Wieland H.A., Willim K.D., Entzeroth M., Wienen W., Beck-Sickinger A.G., Doods H.N. Eur. J. Pharmacol. 271:1994;11.
16. Morgan D.G.A., Small C.J., Abusnana S., Turton M., Gunn I., Heath M., Rossi M., Goldstone A.P., O'Shea D., Meeran K., Smith D.M., Bloom S. Regul. Pept. 75-76:1998;377.
17. Wieland H.A., Engel W., Eberlein M., Rudolf K., Doods H.N. Brit. J. Pharmacol. 125:1998;549.
18. Doods H.N., Engel W., Wieland H.A., Eberlein W., Rudolf K., Judge M., Hamilton B.S. Regul. Pept. 71:1997;212.
19. Doods H.N., Wieland H.A., Engel W., Eberlein W., Willim K.-D., Entzeroth M., Wienen W., Rudolf K. Regul. Pept. 65:1996;71.
20. Hipskind P.A., Lobb K.L., Nixon J.A., Britton T.C., Bruns R.F., Catlow J., Dieckman-McGinty D.K., Gackenheimer S.L., Gitter B.D., Iyengar S., Schober D.A., Simmons R.M.A., Swanson S., Zarrinmayeh H., Zimmerman D.M., Gehlert D.R. J. Med. Chem. 40:1997;3712.
21. Kanatani A., Kanno T., Ishihara A., Hata M., Sakuraba A., Tanaka T., Tsuchiya Y., Mase T., Fukuroda T., Fukami T., Ihara M. Biochem. Biophys. Res. Commun. 266:1999;88.
22. Kanatani A., Hata M., Mashiko S., Ishihara A., Okamoto O., Haga Y., Ohe T., Kanno T., Murai N., Ishii Y., Fukuroda T., Fukami T., Ihara M. Mol. Pharmacol. 59:2001;501.
23. Poindexter G.S., Bruce M.A., LeBoulluec K.L., Monkovic I., Martin S.W., Parker E.M., Iben L.G., McGovern R.T., Ortiz A.A., Stanley J.A., Mattson G.K., Kozlowski M., Arcuri M., Antal-Zimanyi I. Bioorg. Med. Chem. Lett. 12:2002;379.
24. 2. These descriptors were calculated using Windows XP ACD Software (Version 5).
25. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Adv. Drug Deliv. Rev. 23:1997;3.
26. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. J. Med. Chem. 45:2002;2615.
27. Bossert, F., Vater, W. US Patent 3,485,847, 1969.
28. Goldmann S., Born L., Kazda S., Pittel B., Schram M. J. Med. Chem. 33:1990;1413.
29. Valli V.L.K., Alper H. J. Org. Chem. 60:1995;257.
30. Artursson P., Palm K., Luthman K. Drug. Deliv. Rev. 22:1996;67.
31. Krämer S.D. Pharm. Sci. Tech. Today. 2:1999;373.
32. Goodwin J.T., Conradi R.A., Ho N.F.H., Burton P.S. J. Med. Chem. 44:2001;3721.
33. Conradi R.A., Hilgers A.R., Ho N.F.H., Burton P.S. Pharm. Res. 8:1991;1453.
34. Karls M.S., Rush B.D., Wilkinson K.F., Vidmar T.J., Burton P.S., Ruwart M.J. Pharm. Res. 8:1991;1477.
35. An alternative explanation to the enhancement of Caco-2 cell permeabilities for the N-methyl urea derivatives 4b and 8, but not N-methyldihydropyridine 12 could possibly be due to favorable conformational effects and solute volume.
36. Nagao Y., Hagiwara Y., Yamada S., Masahito O., Fujita E. Chem. Pharm. Bull. 32:1984;4686.
37. Chesney A., Markó I.E. Synth. Commun. 20:1990;3167.
38. Tilley J.W., Ramuz H.F., Gerold M. J. Med. Chem. 23:1980;1438.
39. Durant G.J., Emmett C.R., Ganellin C.R., Miles P.D., Parsons M.E., Prain H.D., White G.R. J. Med. Chem. 20:1977;901.
40. Oyler A.R., Naldi R.E., Stefanick S.M., Lloyd J.R., Graden D.A., Cotter M.L. J. Pharm. Sci. 78:1989;21.
41. Young R.C., Durant G.J., Emmett J.C., Ganellin C.R., Graham M.J., Mitchell R.C., Prain H.D., Roantree M.L. J. Med. Chem. 29:1986;44.
42. Durant G.J., Ganellin C.R., Hills D.W., Miles P.D., Parsons M.E., Pepper E.S., White G.R. J. Med. Chem. 28:1985;1414.
43. Karady S., Amato J.S., Dortmund D., Weinstock L.M. Heterocycles. 16:1981;1561.
44. Reddy N.L., Hu L.-Y., Cotter R.E., Fischer J.B., Wong W.J., McBurney R.N., Weber E., Holmes D.L., Wong S.T., Prasad R., Keana J.F.W. J. Med. Chem. 37:1994;260.
45. Two isomeric products are theoretically possible from these condensation cyclizations. In both instances it was reasoned the unsubstituted nitrogen (for 34), and the N-alkyl substituted nitrogen (for 35), would be more nucleophilic than the N-aryl nitrogen, and would preferentially participate in the condensation to furnish the desired imidazolone products. Thus, as an example in the formation of 35, isomer i would be preferentially favored over isomer ii. Heteronuclear multiple bond correlation (HMBC) analysis confirmed the structural assignments for both 34 and 35 were correct.
46. Scatchard G. Ann. N. Y. Acad. Sci. 51:1949;660.
47. Schild H.O. Brit. J. Pharmacol. 2:1947;189.
48. 27a,36.
49. Ganellin R. J. Med. Chem. 24:1981;913.
50. Pirotte B., Dupont L., de Tullio P., Masereel B., Schynts M., Delarge J. Helv. Chim. Acta. 76:1993;1311.
51. Shibata M., Kagawa K., Morisaka K., Ishida T., Inohue M. Acta Crystallogr., Sect. C. 39:1983;1855.
52. Komoto T., Hirota H., Otsuka M., Kotake J., Hasegawa S., Koya H., Sato S., Sakamoto T. Chem. Pharm. Bull. 48:2000;1978.
53. 6, not all of the 29 carbon resonances could be differentiated with confidence from the solvent baseline and hence only 11 are reported.
54. Bradford M. Anal. Biochem. 72:1976;248.
55. Cheng M.S., Prusoff W.H. Biochemistry. 16:1977;3310.
56. Chong S., Dando S.A., Morrison R.A. Pharm. Res. 14:1997;1835.